The SIMPLAAFY randomized clinical trial evaluated three antithrombotic strategies in 1,857 patients with nonvalvular atrial fibrillation following successful left atrial appendage closure (LAAC). Patients received dual antiplatelet therapy (DAPT) for six months, reduced-dose non-vitamin K oral anticoagulants (NOACs) for three months followed by aspirin, or aspirin alone.At six months, the composite of death, stroke, systemic embolism, or major bleeding occurred in 6.9% of the DAPT group, 5.1% of the reduced-dose NOAC group, and 3.3% of the aspirin-only group. Both monotherapy strategies met the prespecified noninferiority criteria (P<.001).Major bleeding rates were 4.5%, 2.7%, and 1.7%, respectively.
Device-related thrombus rates were 3.4%, 0.9%, and 2.7%, respectively. Reduced-dose NOACs and aspirin alone were noninferior to DAPT for six-month clinical outcomes after uncomplicated…